← Back to Search

Corticosteroid

Dexamethasone for Non-Small Cell Lung Cancer

N/A
Waitlist Available
Led By Anthony Shields
Research Sponsored by Barbara Ann Karmanos Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Study Summary

This trial is testing the effects of dexamethasone on lung cancer patients who have not responded to previous treatment. Imaging tests will be used to see if dexamethasone affects how tumors grow and respond to treatments.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 6-9
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 6-9 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in tumor SUVmax assessed by 18F-FLT PET imaging
Secondary outcome measures
Change in senescence markers in circulating tumor cells
Change in serum dexamethasone concentration
Dexamethasone withdrawal as measured by changes in tumor FLT retention
+1 more

Side effects data

From 2013 Phase 4 trial • 122 Patients • NCT01474915
2%
Cerebrospinal fluid leak
2%
Deep Vein Thrombosis
2%
Fever
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ondansetron
Aprepitant

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (dexamethasone, 18F-FLT PET)Experimental Treatment4 Interventions
Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography
2008
Completed Phase 2
~2210
Dexamethasone
2007
Completed Phase 4
~2590

Find a Location

Who is running the clinical trial?

Barbara Ann Karmanos Cancer InstituteLead Sponsor
163 Previous Clinical Trials
9,250 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,721 Previous Clinical Trials
40,965,052 Total Patients Enrolled
Anthony ShieldsPrincipal InvestigatorBarbara Ann Karmanos Cancer Institute
2 Previous Clinical Trials
8 Total Patients Enrolled

Media Library

Dexamethasone (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT02819024 — N/A
Non-Small Cell Lung Cancer Research Study Groups: Treatment (dexamethasone, 18F-FLT PET)
Non-Small Cell Lung Cancer Clinical Trial 2023: Dexamethasone Highlights & Side Effects. Trial Name: NCT02819024 — N/A
Dexamethasone (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02819024 — N/A
~1 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top